Valuation: BioGaia AB

Market Cap 11.13B 1.13B 987M 929M 846M 1.59B 108B 1.59B 4.29B 55.22B 4.25B 4.16B 178B P/E 2026 *
28.8x
P/E 2027 * 23.5x
Enterprise Value 10.46B 1.06B 927M 873M 795M 1.49B 102B 1.49B 4.03B 51.91B 4B 3.91B 168B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 5.59x
Free-Float
80.82%
Yield 2026 *
2.68%
Yield 2027 * 2.91%
1 day+1.94%
1 week+2.41%
Current month-5.66%
1 month-5.75%
3 months-8.32%
6 months-2.84%
Current year+0.93%
1 week 9.48
Extreme 9.48
9.76
1 month 9.48
Extreme 9.48
10.61
Current year 9.12
Extreme 9.12
12.32
1 year 8.76
Extreme 8.76
12.32
3 years 7.9
Extreme 7.905
12.32
5 years 6.64
Extreme 6.645
12.32
10 years 5
Extreme 4.9968
12.32
Manager TitleAgeSince
Chief Executive Officer 60 2023-09-29
Director of Finance/CFO 59 2019-11-04
Chief Operating Officer 49 2020-12-31
Director TitleAgeSince
Chairman 77 2002-12-31
Chairman 76 2018-04-24
Director/Board Member 46 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%+2.41% - - 1.13B
+1.34%-0.07%+33.16%-3.66% 78.37B
+8.59%+13.90%+529.05%+66.69% 61.5B
+1.54%+6.70%-10.12%-32.11% 59.78B
+0.29%-0.92%-10.95%+26.82% 46.53B
+1.92%+0.76%+2.71%+154.99% 45.5B
+2.28%+1.65%+57.08%-14.67% 31.84B
+0.69%+3.22%+48.86%+114.46% 25.4B
+6.00%+9.46%+11.24%+166.67% 21.43B
-0.76%-1.03%+57.53%+103.49% 15.77B
Average +2.36%+1.73%+79.84%+64.74% 42.9B
Weighted average by Cap. +2.63%+1.66%+99.32%+46.20%

Financials

2026 *2027 *
Net sales 1.67B 170M 148M 139M 127M 238M 16.26B 238M 643M 8.28B 638M 624M 26.73B 1.88B 191M 166M 157M 143M 268M 18.28B 268M 723M 9.31B 717M 701M 30.05B
Net income 387M 39.35M 34.31M 32.31M 29.43M 55.18M 3.77B 55.24M 149M 1.92B 148M 145M 6.2B 474M 48.2M 42.02M 39.58M 36.04M 67.58M 4.62B 67.66M 183M 2.35B 181M 177M 7.59B
Net Debt -667M -67.82M -59.13M -55.69M -50.72M -95.1M -6.5B -95.22M -257M -3.31B -255M -249M -10.68B -646M -65.64M -57.23M -53.9M -49.09M -92.03M -6.29B -92.15M -249M -3.2B -247M -241M -10.34B
Logo BioGaia AB
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Employees
251
Date Price Change
26-09-21 9.755 +2.15%
26-09-18 €9.550 +0.69%
26-09-17 €9.485 +0.05%
26-09-16 €9.480 -0.42%
26-09-15 €9.520 -0.05%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
110.00SEK
Average target price
152.50SEK
Spread / Average Target
+38.64%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!